Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep

Vaccine

Volumn 27, Issue 31, 2009, Pages 4169-4175

  Eschbaumer, Michael ^a   Hoffmann, Bernd ^a   König, Patricia ^a   Teifke, Jens P ^a   Gethmann, Jörn M ^a   Conraths, Franz J ^a   Probst, Carolina ^a   Mettenleiter, Thomas C ^a   Beer, Martin ^a  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

Author keywords

Bluetongue; Efficacy; Inactivated vaccine; Sheep

Indexed keywords

BLUEVAC 8; BTVPUR ALSAP 8; INACTIVATED VACCINE; UNCLASSIFIED DRUG; ZULVAC 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; BLUETONGUE ORBIVIRUS; BLUETONGUE VIRUS SEROTYPE 8; CONTROLLED STUDY; EUROPEAN UNION; FEMALE; GERMANY; IMMUNIZATION; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; SHEEP; SHEEP DISEASE; SWITZERLAND; VACCINATION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; BLUETONGUE; BLUETONGUE VIRUS; BODY TEMPERATURE; FEMALE; GERMANY; NEUTRALIZATION TESTS; SHEEP; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 67349150456     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.056     Document Type: Article

References (46)

1. Schwartz-Cornil I., Mertens P.P.C., Contreras V., Hemati B., Pascale F., Bréard E., et al. Bluetongue virus: virology, pathogenesis and immunity. Vet Res 39 September-October (5) (2008) 46
2. Hofmann M.A., Renzullo S., Mader M., Chaignat V., Worwa G., and Thuer B. Genetic characterization of toggenburg orbivirus, a new bluetongue virus, from goats, Switzerland. Emerg Infect Dis 14 December (12) (2008) 1855-1861
3. Wilson A., and Mellor P. Bluetongue in Europe: vectors, epidemiology and climate change. Parasitol Res 103 Suppl. 1 (2008) S69-S77
4. Saegerman C., Berkvens D., and Mellor P.S. Bluetongue epidemiology in the European Union. Emerg Infect Dis 14 April (4) (2008) 539-544
5. European Commission. Commission Regulation (EC) No. 1266/2007 of 26 October 2007 on implementing rules for Council Directive 2000/75/EC as regards the control, monitoring, surveillance and restrictions on movements of certain animals of susceptible species in relation to bluetongue. Off J Eur Union L283/37 October (2007)
6. European Food Safety Authority (EFSA). Report on epidemiological analysis of the 2006 bluetongue virus serotype 8 epidemic in north-western Europe. Parma: EFSA; 2007. Available from: http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902103240.htm.
7. Hoffmann B., Saßerath M., Thalheim S., Bunzenthal C., Strebelow G., and Beer M. Bluetongue virus serotype 8 reemergence in Germany, 2007 and 2008. Emerg Infect Dis 14 September (9) (2008) 1421-1423
8. Conraths F.J., Gethmann J.M., Staubach C., Mettenleiter T.C., Beer M., and Hoffmann B. Epidemiology of bluetongue virus serotype 8, Germany. Emerg Infect Dis 15 3 (2009) 433-435
9. European Commission, Health & Consumers Directorate-General (SANCO). Report of the Working Group on bluetongue held on 2 March 2009 (2009), SANCO, Brussels SANCO/5023/2009
10. Mintiens K., Méroc E., Mellor P.S., Staubach C., Gerbier G., Elbers A.R., et al. Possible routes of introduction of bluetongue virus serotype 8 into the epicentre of the 2006 epidemic in north-western Europe. Prev Vet Med 87 October (1-2) (2008) 131-144
11. Caporale V., Giovannini A., Patta C., Calistri P., Nannini D., and Santucci U. Vaccination in the control strategy of bluetongue in Italy. Dev Biol (Basel) 119 (2004) 113-127
12. Savini G., MacLachlan N.J., Sánchez-Vizcaíno J.M., and Zientara S. Vaccines against bluetongue in Europe. Comp Immunol Microbiol Infect Dis 31 March (2-3) (2008) 101-120
13. Bhanuprakash V., Indrani B.K., Hosamani M., Balamurugan V., and Singh R.K. Bluetongue vaccines: the past, present and future. Expert Rev Vaccines 8 February (2) (2009) 191-204
14. European Commission. 2008/655/EC: Commission Decision of 24 July 2008 approving the emergency vaccination plans against bluetongue of certain Member States and fixing the level of the Community's financial contribution for 2007 and 2008. Off J Eur Union L214/66 August (2008)
15. Savini G., Hamers C., Conte A., Migliaccio P., Bonfini B., Teodori L., et al. Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle. Vet Microbiol 133 January (1-2) (2009) 1-8
16. Veronesi E., Hamblin C., and Mellor P.S. Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae). Vaccine 23 December (48-49) (2005) 5509-5516
17. Ferrari G., De Liberato C., Scavia G., Lorenzetti R., Zini M., Farina F., et al. Active circulation of bluetongue vaccine virus serotype-2 among unvaccinated cattle in central Italy. Prev Vet Med 68 May (2-4) (2005) 103-113
18. Batten C.A., Maan S., Shaw A.E., Maan N.S., and Mertens P.P. A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. Virus Res 137 October (1) (2008) 56-63
19. European Commission, Health & Consumers Directorate-General (SANCO), Scientific Committee on Animal Health and Animal Welfare. Possible use of vaccination against bluetongue in Europe. Brussels: SANCO; 2000. SANCO/C3/AH/R19/2000. Available from: http://ec.europa.eu/food/fs/sc/scah/out47_en.pdf.
20. Saegerman C., Hubaux M., Urbain B., Lengelé L., and Berkvens D. Regulatory issues surrounding the temporary authorisation of animal vaccination in emergency situations: the example of bluetongue in Europe. Rev Sci Tech 26 August (2) (2007) 395-413
21. Enserink M. Animal disease. Exotic disease of farm animals tests Europe's responses. Science 319 February (5864) (2008) 710-711
22. Office International des Epizooties (OIE). Bluetongue. In: Manual of diagnostic tests and vaccines for terrestrial animals. Paris: OIE; 2008. Available from: http://www.oie.int/eng/normes/mmanual/2008/pdf/2.01.03_BLUETONGUE.pdf.
23. Savini G., Ronchi G.F., Leone A., Ciarelli A., Migliaccio P., Franchi P., et al. An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy. Vet Microbiol 124 September (1-2) (2007) 140-146
24. German Federal Ministry of Food, Agriculture and Consumer Protection (BMELV). Pressemitteilung Nr. 133 vom 1. September 2008 [press release]. Berlin: BMELV; 2008. Available from: http://www.bmelv.de/cln_044/nn_752324/DE/12-Presse/Pressemitteilungen/2008/133-Bilanz_20Blauzungenkrankheit.html__nnn=true.
25. The European Parliament and the Council of the European Union. Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products. Off J Eur Commun 2001;L311/1(November).
26. European Medicines Agency (EMEA) Committee for Medicinal Products for Veterinary Use (CVMP). Guideline on requirements for an authorisation under exceptional circumstances for vaccines for emergency use against bluetongue. London: EMEA; 2008. EMEA/CVMP/IWP/220193/2008. Available from: http://www.emea.europa.eu/pdfs/vet/iwp/22019308enfin.pdf.
27. BMELV. Pressemitteilung Nr. 027 vom 14. February 2008 [press release]. Berlin: BMELV; 2008. Available from: http://www.bmelv.de/cln_044/nn_752324/DE/12-Presse/Pressemitteilungen/2008/027-Blauzungenkrankheit.html__nnn=true.
28. Gethmann J., Hüttner K., Heyne H., Probst C., Ziller M., Beer M., et al. Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions. Vaccine 27 (2009) 4118-4126
29. Toussaint J.F., Sailleau C., Bréard E., Zientara S., and De Clercq K. Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments. J Virol Methods 140 March (1-2) (2007) 115-123
30. Batten C.A., Bachanek-Bankowska K., Bin-Tarif A., Kgosana L., Swain A.J., Corteyn M., et al. Bluetongue virus: European Community inter-laboratory comparison tests to evaluate ELISA and RT-PCR detection methods. Vet Microbiol 129 May (1-2) (2008) 80-88
31. Savini G., Nicolussi P., Pilo G., Colorito P., Fresi S., Teodori L., et al. Study of the safety and efficacy of a recombinant vaccine for bluetongue virus serotype 2. Vet Ital 43 October-December (4) (2007) 815-820
32. Mayr A., Bachmann P.A., Bibrack B., and Wittmann G. Quantitative Bestimmung der Virusinfektiosität (Virustitration). Virologische Arbeitsmethoden, Band I (1974), VEB Gustav Fischer Verlag, Jena p. 35-9
33. MacLachlan N.J., Crafford J.E., Vernau W., Gardner I.A., Goddard A., Guthrie A.J., et al. Experimental reproduction of severe bluetongue in sheep. Vet Pathol 45 May (3) (2008) 310-315
34. Stevens D.R., Stott J., Osburn B.I., Giles R., Wiesehahn G.P., and Barber T.L. Potency and efficacy of inactivated bluetongue virus vaccines. Prog Clin Biol Res 178 (1985) 649-652
35. Ramakrishnan M.A., Pandey A.B., Singh K.P., Singh R., Nandi S., and Mehrotra M.L. Immune responses and protective efficacy of binary ethylenimine (BEI)-inactivated bluetongue virus vaccines in sheep. Vet Res Commun 30 November (8) (2006) 873-880
36. Berry L.J., Osburn B.I., Stott J.L., Farver T., Heron B., and Patton W. Inactivated bluetongue virus vaccine in lambs: differential serological responses related to breed. Vet Res Commun 5 May (3) (1982) 289-293
37. Parker J., Herniman K.A., Gibbs E.P., and Sellers R.F. An experimental inactivated vaccine against bluetongue. Vet Rec 96 March (13) (1975) 284-287
38. Di Emidio B., Nicolussi P., Patta C., Ronchi G.F., Monaco F., Savini G., et al. Efficacy and safety studies on an inactivated vaccine against bluetongue virus serotype 2. Vet Ital 40 October-December (4) (2004) 640-644
39. Stott J.L., Barber T.L., and Osburn B.I. Immunologic response of sheep to inactivated and virulent bluetongue virus. Am J Vet Res 46 May (5) (1985) 1043-1049
40. Rendi-Wagner P., Shouval D., Genton B., Lurie Y., Rümke H., Boland G., et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24 April (15) (2006) 2781-2789
41. Burton J.L., Burnside E.B., Kennedy B.W., Wilkie B.N., and Burton J.H. Antibody responses to human erythrocytes and ovalbumin as marker traits of disease resistance in dairy calves. J Dairy Sci 72 May (1989) 1252-1265
42. Tabachnick W.J., MacLachlan N.J., Thompson L.H., Hunt G.J., and Patton J.F. Susceptibility of Culicoides variipennis sonorensis to infection by polymerase chain reaction-detectable bluetongue virus in cattle blood. Am J Trop Med Hyg 54 May (5) (1996) 481-485
43. Bonneau K.R., DeMaula C.D., Mullens B.A., and MacLachlan N.J. Duration of viraemia infectious to Culicoides sonorensis in bluetongue virus-infected cattle and sheep. Vet Microbiol 88 August (2) (2002) 115-125
44. Clavijo A., Heckert R.A., Dulac G.C., and Afshar A. Isolation and identification of bluetongue virus. J Virol Methods 87 June (1-2) (2000) 13-23
45. Darpel K.E., Batten C.A., Veronesi E., Shaw A.E., Anthony S., Bachanek-Bankowska K., et al. Clinical signs and pathology shown by British sheep and cattle infected with bluetongue virus serotype 8 derived from the 2006 outbreak in northern Europe. Vet Rec 161 August (8) (2007) 253-261
46. EMEA CVMP. An overview of field safety data from the EU for bluetongue virus vaccines serotype 8 emerging from the 2008 national vaccination campaigns. London: EMEA; 2009. EMEA/CVMP/652019/2008. Available from: http://www.emea.europa.eu/pdfs/vet/press/pos/65201908en.pdf.